Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Trial info for A2-73, Blarcamesine, aka AE37. as

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
tradeherpete Member Profile
 
Followed By 34
Posts 2,852
Boards Moderated 0
Alias Born 03/20/14
160x600 placeholder
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference GlobeNewswire Inc. - 10/15/2021 7:00:00 AM
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease GlobeNewswire Inc. - 10/13/2021 7:00:00 AM
Cassava down after phase 3 simufilam announcement; other Alzheimer's names follow Seeking Alpha - 10/6/2021 12:51:22 PM
CEO Presenting on the Emerging Growth Conference on September 29  Register Now InvestorsHub NewsWire - 9/28/2021 8:00:00 AM
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021 GlobeNewswire Inc. - 9/27/2021 9:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:11:01 AM
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market® GlobeNewswire Inc. - 9/27/2021 7:00:00 AM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 9/24/2021 5:05:26 PM
Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/20/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference Today!  Register Now InvestorsHub NewsWire - 9/15/2021 7:00:00 AM
Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire Inc. - 9/9/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference Today.  Register Now InvestorsHub NewsWire - 9/1/2021 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism) GlobeNewswire Inc. - 8/26/2021 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/12/2021 5:13:54 PM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results GlobeNewswire Inc. - 8/12/2021 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021 GlobeNewswire Inc. - 8/5/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 5:41:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 5:39:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 5:36:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 5:31:15 PM
CEO Presenting on the Emerging Growth Conference Today.  Register Now InvestorsHub NewsWire - 8/4/2021 7:00:00 AM
Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021 GlobeNewswire Inc. - 8/4/2021 7:00:00 AM
Cassava Sciences drags rivals lower amid concerns over its Alzheimer’s drug Seeking Alpha - 7/30/2021 9:03:44 AM
Anavex Life Sciences rises on positive data for Alzheimer’s therapy in mouse study Seeking Alpha - 7/29/2021 7:46:45 AM
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease GlobeNewswire Inc. - 7/29/2021 7:00:00 AM
tradeherpete   Tuesday, 11/24/20 08:24:09 AM
Re: None
Post # of 333376 
Trial info for A2-73, Blarcamesine, aka AE37. as a vaccine for Breast and Prostate Cancer


Vaccine Therapy in Treating Patients With Breast Cancer
Phase 2
Completed
2020-03-30
NCT04314934


https://pubchem.ncbi.nlm.nih.gov/compound/Blarcamesine#section=Drug-and-Medication-Information

AE37: a novel T-cell-eliciting vaccine for breast cancer

Abstract

Introduction: Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8(+) T-cell-eliciting vaccines. AE37 is a promising primarily CD4(+) T-cell-eliciting HER-2/neu breast cancer vaccine currently in clinical trials.

Areas covered: This article reviews preclinical investigations as well as findings from completed and ongoing Phase I and Phase II clinical trials of the AE37 vaccine.

Expert opinion: Clinical trials have shown the AE37 vaccine to be safe and capable of generating peptide-specific, durable immune responses. This has been shown in patients with any level of HER-2/neu expression. Early clinical findings suggest there may be benefit to AE37 vaccination in preventing breast cancer recurrence.


Prostate Cancer

Results: Toxicities beyond grade 2 were not observed. Seventy-five percent of patients developed augmented immunity to the AE37 vaccine and 65% to the unmodified AE36 peptide as detected in the IFN-gamma-based ELISPOT assay. Intracellular IFN-gamma analyses revealed that AE37 elicited both CD4(+) and CD8(+) T-cell responses. Eighty percent of the patients developed a positive delayed-type hypersensitivity reaction to AE36. Additionally, significant decreases could be detected in circulating Treg frequencies, plasma HER-2/neu, and serum transforming growth factor-beta levels. Patients with less extensive disease developed better immunologic responses on vaccination.

Conclusion: AE37 vaccine is safe and can induce HER-2/neu-specific cellular immune responses in patients with castrate-sensitive and castrate-resistant prostate cancer, thus emphasizing the potential of AE37 to target HER-2/neu for the immunotherapy of prostate cancer.

https://pubmed.ncbi.nlm.nih.gov/21895539/?dopt=Abstract

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences